AbCellera Biologics Inc. (ABCL)

$9.89

+0.04 (+0.41%)
Rating:
Recommendation:
-
Symbol ABCL
Price $9.89
Beta 0.000
Volume Avg. 1.83M
Market Cap 2.820B
Shares () -
52 Week Range 5.42-17.93
1y Target Est -
DCF Unlevered ABCL DCF ->
DCF Levered ABCL LDCF ->
ROE 18.22% Buy
ROA 12.57% Buy
Operating Margin -
Debt / Equity 31.41% Neutral
P/E 17.05 Strong Buy
P/B 2.32 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ABCL news


Dr. Carl L. Hansen
Healthcare
Biotechnology
NASDAQ Global Select

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.